JAMA : the journal of the American Medical Association
-
Multicenter Study
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction.
Despite 2 decades of evidence demonstrating benefits from prompt coronary reperfusion, registries continue to show that many patients with ST-segment elevation myocardial infarction (STEMI) are treated too slowly or not at all. ⋯ A statewide program focused on regional systems for reperfusion for STEMI can significantly improve quality of care. Further research is needed to ensure that programs that result in improved application of reperfusion treatments will lead to reductions in mortality and morbidity from STEMI.
-
Randomized Controlled Trial Multicenter Study
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
Plasma concentrations of the vasoconstrictor peptide endothelin-1 are increased in patients with heart failure, and higher concentrations are associated with worse outcomes. Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemodynamic actions in heart failure. ⋯ The endothelin receptor antagonist tezosentan did not improve symptoms or clinical outcomes in patients with acute heart failure.